Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor (Review)

Wang, Shijie; Wu, Pin; Chen, Yongyuan; Chai, Ying

doi:10.3892/ol.2020.11736

Cited by 9 publications

(8 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Innate lymphoid cells (ILCs), a novel population of innate lymphocytes, regulate tissue homeostasis, inflammation, tumorigenesis, and tumor surveillance [ 63 , 64 , 65 , 66 ]. ILCs are divided into three groups: group 1 ILCs, which include natural killer (NK) cells and ILC1s, group 2 ILCs (ILC2s), and group 3 ILCs, which include lymphoid tissue-inducer (LTi) cells and ILC3s.…”

Section: Cell Types Engaged In Cancer-associated Inflammationmentioning

confidence: 99%

“…ILCs are divided into three groups: group 1 ILCs, which include natural killer (NK) cells and ILC1s, group 2 ILCs (ILC2s), and group 3 ILCs, which include lymphoid tissue-inducer (LTi) cells and ILC3s. Group 1 ILCs are predominantly anti-tumorigenic, whereas group 2 and 3 ILCs are mostly considered to be pro-tumorigenic [ 63 ]. Although the role of NK cells in cancer is well established, the studies on other ILC subsets in cancer are limited and their roles in inflammation-induced tumorigenesis and metastasis as well as anti-cancer immunity are now under investigation.…”

Section: Cell Types Engaged In Cancer-associated Inflammationmentioning

confidence: 99%

See 1 more Smart Citation

Inflammation-Induced Tumorigenesis and Metastasis

Hibino

Kawazoe

Kasahara

et al. 2021

IJMS

123

View full text Add to dashboard Cite

Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and metastasis through various mechanisms and is now recognized as a hallmark of cancer and an attractive therapeutic target in cancer. In this review, we discuss recent advances in molecular mechanisms of how inflammation promotes tumorigenesis and metastasis and suppresses anti-tumor immunity in various types of solid tumors, including esophageal, gastric, colorectal, liver, and pancreatic cancer as well as hematopoietic malignancies.

show abstract

Section: Cell Types Engaged In Cancer-associated Inflammationmentioning

confidence: 99%

Section: Cell Types Engaged In Cancer-associated Inflammationmentioning

confidence: 99%

Inflammation-Induced Tumorigenesis and Metastasis

Hibino

Kawazoe

Kasahara

et al. 2021

IJMS

123

View full text Add to dashboard Cite

show abstract

“…Even though the number of studies focusing on the role of ILC2s in controlling tumor growth has increased considerably in the last decade, at present, a clear definition of these cells in TME of different tumors is not available [ 155 , 156 , 157 ]. In the future, the establishment of novel mouse models constitutively or transiently lacking ILC2s will be crucial to better define the role of these cells in conditioning tumor immunity.…”

Section: Discussionmentioning

confidence: 99%

Group 2 Innate Lymphoid Cells: A Double-Edged Sword in Cancer?

Maggi

Veneziani

Moretta

et al. 2020

Cancers

View full text Add to dashboard Cite

Group 2 Innate Lymphoid Cells (ILC2s) belong to the family of helper ILCs which provide host defense against infectious agents, participate in inflammatory responses and mediate lymphoid organogenesis and tissue repair, mainly at the skin and mucosal level. Based on their transcriptional, phenotypic and functional profile, ILC2s mirror the features of the adaptive CD4+ Th2 cell subset, both contributing to the so-called type 2 immune response. Similar to other ILCs, ILC2s are rapidly activated by signals deriving from tissue and/or other tissue-resident immune cells. The biologic activity of ILCs needs to be tightly regulated in order to prevent them from contributing to severe inflammation and damage in several organs. Indeed, ILC2s display both enhancing and regulatory roles in several pathophysiological conditions, including tumors. In this review, we summarize the actual knowledge about ILC2s ability to induce or impair a protective immune response, their pro- or antitumor activity in murine models, human (children and adults) pathologies and the potential strategies to improve cancer immunotherapy by exploiting the features of ILC2s.

show abstract

“…Due to the secretion of cytokines involved in promoting tumour growth and blocking antitumour immunity in the microenvironment, ILC2 is widely recognised as a cell subtype with protumour properties [ 96 ]. It has been shown that the ILC2/IL-13/myeloid-derived suppressor target (MDSC) axis contributes to creating the immunosuppressive microenvironment of acute promyelocytic leukaemia and many lithium tumours [ 97 , 98 , 99 ]. Undoubtedly, a desirable direction of research would be to also investigate the role of the ILC2/IL-13/MDSC axis in the pathogenesis of MM.…”

Section: Innate Lymphoid Cells In the Development Of Multiple Myelomamentioning

confidence: 99%

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy

Szudy‐Szczyrek

Ahern

Kozioł

et al. 2021

Cancers

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) are a recently identified family of lymphocyte-like cells lacking a specific antigen receptor. They are part of the innate immune system. They play a key role in tissue homeostasis and also control inflammatory and neoplastic processes. In response to environmental stimuli, ILCs change their phenotype and functions, and influence the activity of other cells in the microenvironment. ILC dysfunction can lead to a wide variety of diseases, including cancer. ILC can be divided into three subgroups: ILC Group 1, comprising NK cells and ILC1; Group 2, including ILC2 alone; and Group 3, containing Lymphoid Tissue inducers (LTi) and ILC3 cells. While Group 1 ILCs mainly exert antitumour activity, Group 2 and Group 3 ILCs are protumorigenic in nature. A growing body of preclinical and clinical data support the role of ILCs in the pathogenesis of multiple myeloma (MM). Therefore, targeting ILCs may be of clinical benefit. In this manuscript, we review the available data on the role of ILCs in MM immunology and therapy.

show abstract

Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor (Review)

Cited by 9 publications

References 106 publications

Inflammation-Induced Tumorigenesis and Metastasis

Inflammation-Induced Tumorigenesis and Metastasis

Group 2 Innate Lymphoid Cells: A Double-Edged Sword in Cancer?

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy

Contact Info

Product

Resources

About